Early Treatment of High-Risk Smoldering Multiple Myeloma Improves Outcomes

Early treatment with lenalidomide and dexamethasone in patients with high-risk smoldering myeloma significantly delayed progression to symptomatic disease and prolonged survival with a good safety profile.
Source: Cancer Network - Category: Cancer & Oncology Source Type: news

Related Links:

This study strongly suggests that ASCT2 is an excellent target molecule for the treatment of malignancies, especiallyKRAS‐mutated cancers. AbstractKRAS mutations are detected in numerous human cancers, but there are few effective drugs forKRAS‐mutated cancers. Transporters for amino acids and glucose are highly expressed on cancer cells, possibly to maintain rapid cell growth and metabolism. Alanine‐serine‐cysteine transporter 2 (ASCT2) is a primary transporter for glutamine in cancer cells. In this study, we developed a novel mono clonal antibody (mAb) recognizing the extracellular domain of human ASCT2, and inves...
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research
Publication date: Available online 21 October 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Giulia Gabrielli, Alessandro Broccoli, Cinzia Pellegrini, Lisa Argnani, Michele Cavo, Pier Luigi Zinzani
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
AbstractHematologic malignancies include several lymphoproliferative and myeloproliferative disorders, many of which are frequently encountered in current health care settings. These malignancies frequently affect the gastrointestinal (GI) tract, either by secondary extranodal or extramedullary extension to the GI tract, or as a primary process arising in the GI tract. In fact, the GI tract may represent the most common extranodal site of involvement in many of them, such as lymphoma. Furthermore, in the current era of improved cancer treatment and advanced transplant procedures with increased survival, it has been quite c...
Source: Abdominal Imaging - Category: Radiology Source Type: research
Irutė Girkontaitė In this work, we have investigated the feasibility of sub-microsecond range irreversible electroporation (IRE) with and without calcium electroporation in vivo. As a model, BALB/C mice were used and bioluminescent SP2/0 myeloma tumor models were developed. Tumors were treated with two separate pulsed electric field (PEF) pulsing protocols PEF1: 12 kV/cm × 200 ns × 500 (0.006 J/pulse) and PEF2: 12 kV/cm × 500 ns × 500 (0.015 J/pulse), which were delivered with and without Ca2+ (168 mM) using parallel plate electrodes at a repetition frequency of 100 Hz. Both P...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
So far, CRISPR has only been tried in three patients, two with multiple myeloma and one with a sarcoma. All had tried standard treatments, to no avail.
Source: WebMD Health - Category: Consumer Health News Source Type: news
My (predictable) answer is “NO, absolutely NOT.” Not until you begin having CRAB symptoms. But first things first… I began writing this post last week, then I just had too many things to do so I didn’t finish my draft. Then, yesterday morning, before going to work, I came across an article by Dr. Brian Durie (I don’t think I need to explain who he is!) making some of the points I had already made in my draft, BUT from the point of view of a world-famous hematologist. So I decided to cut my draft in half and give you the link to Dr. Durie’s piece: http://bit.ly/2WWwsX9 But, of cours...
Source: Margaret's Corner - Category: Cancer & Oncology Authors: Tags: Blogroll HR SMM lenalidomide Source Type: blogs
ConclusionsOur results demonstrate that in vitro activation affects NK cell anti-myeloma activity in vivo by regulating their BM infiltration. Furthermore, we provided direct evidence that CXCR3 restrains NK cell anti-tumor capacity in vivo according to the activation protocol used, and that the effects of NK cell-based adoptive immunotherapy for multiple myeloma can be improved by increasing their bone marrow homing through CXCR3 inhibition.
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research
Survival data from the Connect MM Registry, which is representative of the national MM population, reflect national trends of improvement. This establishes the Connect MM Registry as a reference for MM survival in the US. AbstractBackgroundThe Surveillance, Epidemiology, and End Results (SEER) database and National Cancer Database (NCDB) show improved overall survival (OS) in patients with multiple myeloma (MM) over the last 15  years. This analysis evaluated the validity of the largely community‐based Connect MM Registry as a national reference for MM.MethodsBaseline disease characteristics and survival in US newly...
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research
The initial findings from a small clinical trial of patients with multiple myeloma or sarcoma suggest that gene-edited immunotherapy is safe.
Source: The Scientist - Category: Science Tags: News & Opinion Source Type: news
CONCLUSION: There are a great number of nanoparticulate drug delivery systems for potential use in cancer therapy including non-targeted and targeted nanoparticles. Promising results to date using bortezomib nanoparticles for cancer treatment should lead to the implementation of further research with nanoparticulate-based drug delivery systems. PMID: 31692424 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - Category: Drugs & Pharmacology Authors: Tags: Curr Pharm Des Source Type: research
More News: Cancer | Cancer & Oncology | Dexamethasone | Myeloma | Revlimid